Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

281 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J, Sandström M, Wester K, Tolmachev V, Orlova A. Malmberg J, et al. Nucl Med Biol. 2011 Nov;38(8):1093-102. doi: 10.1016/j.nucmedbio.2011.04.005. Epub 2011 Jun 22. Nucl Med Biol. 2011. PMID: 22137850
Evaluation of real-time immunohistochemistry and interaction map as an alternative objective assessment of HER2 expression in human breast cancer tissue.
Gedda L, Björkelund H, Lebel L, Asplund A, Dubois L, Wester K, Penagos N, Malmqvist M, Andersson K. Gedda L, et al. Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):497-505. doi: 10.1097/PAI.0b013e318281162d. Appl Immunohistochem Mol Morphol. 2013. PMID: 23455178
A new antibody recognizing the vIII mutation of human epidermal growth factor receptor.
Ohman L, Gedda L, Hesselager G, Larsson R, Nister M, Stigbrand T, Wester K, Carlsson J. Ohman L, et al. Tumour Biol. 2002 Mar-Apr;23(2):61-9. doi: 10.1159/000059704. Tumour Biol. 2002. PMID: 12065843
The affinity of Ua30:2 was found to be high [K(d) = 45 nM (Biacore) and 80 nM (saturation analysis)]. Immunohistochemistry in tissue sections from human gliomas demonstrated a similar expression pattern for Ua30:2 as for the recently characterized antibodies L8A4 and DH8.3 …
The affinity of Ua30:2 was found to be high [K(d) = 45 nM (Biacore) and 80 nM (saturation analysis)]. Immunohistochemistry in tissue …
HER-2--a possible target for therapy of metastatic urinary bladder carcinoma.
Wester K, Sjöström A, de la Torre M, Carlsson J, Malmström PU. Wester K, et al. Acta Oncol. 2002;41(3):282-8. doi: 10.1080/02841860260088836. Acta Oncol. 2002. PMID: 12195748
EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.
Carlsson J, Wester K, De La Torre M, Malmström PU, Gårdmark T. Carlsson J, et al. Radiol Oncol. 2015 Mar 3;49(1):50-8. doi: 10.2478/raon-2014-0015. eCollection 2015 Mar. Radiol Oncol. 2015. PMID: 25810701 Free PMC article.
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.
Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C. Carlsson J, et al. Br J Cancer. 2004 Jun 14;90(12):2344-8. doi: 10.1038/sj.bjc.6601881. Br J Cancer. 2004. PMID: 15150568 Free PMC article. Review.
Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.
Carlsson J, Ren ZP, Wester K, Sundberg AL, Heldin NE, Hesselager G, Persson M, Gedda L, Tolmachev V, Lundqvist H, Blomquist E, Nistér M. Carlsson J, et al. J Neurooncol. 2006 Mar;77(1):33-45. doi: 10.1007/s11060-005-7410-z. J Neurooncol. 2006. PMID: 16200342 Review.
281 results
Jump to page